PAG
UTHR icon

Poinciana Advisors Group’s United Therapeutics UTHR Stock Holding History

Poinciana Advisors Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Hold
398
– – 0.16% 106
2026
Q1 		$236K Buy
+398
New +$198K 0.19% 107

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Poinciana Advisors Group's UTHR Position: Q2 2026 in Review

Poinciana Advisors Group held its United Therapeutics (UTHR) position steady in Q2 2026 at 398 shares worth $216K. The position accounts for 0.16% of the portfolio, ranked #106.

Poinciana Advisors Group first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $236K in Q1 2026. 417 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Poinciana Advisors Group held 398 shares of United Therapeutics worth $216K as of Q2 2026.
  • Poinciana Advisors Group left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.16% of Poinciana Advisors Group's portfolio in Q2 2026, its #106 holding.
  • Poinciana Advisors Group first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Poinciana Advisors Group's United Therapeutics position peaked at $236K in Q1 2026.
  • 417 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Poinciana Advisors Group's 13F filing for Q2 2026, filed 28 Jul 2026.